http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 crossref DOI: https://dx.doi.org/10.18535/jmscr/v13i01.11



Benefits and Risks of Mammography Screening in Women Ages 40 to 49 Years

Authors

Thamer Saeed Ali Alghamdi¹, Ahmed Ali Alharthi², Yousef Ali Alharbi³, Naif Ali Hamid Althubyani⁴

> ¹Radiology Senior Specialist, Prince Mansour Military Hospital ^{2,3,4}Radiology Specialist, Prince Mansour Military Hospital

Abstract

Mammography is a widely used screening tool for breast cancer. While it has been shown to reduce mortality from breast cancer, its benefits and risks vary depending on the age group being screened. This paper aims to provide a comprehensive review of the benefits and risks of mammography screening specifically in women aged 40 to 49 years. The analysis includes statistical data, benefits in terms of early detection and mortality reduction, as well as the potential risks such as false positives, overdiagnosis, and radiation exposure.

Keywords

- Mammography screening
- Breast cancer
- Early detection
- *Mortality reduction*
- Women aged 40–49 years
- False positives
- Overdiagnosis
- Radiation exposure
- Breast-conserving surgery
- Psychological impact
- Risk assessment
- BRCA mutations
- Breast density
- Comparative effectiveness research
- Shared decision-making
- Screening guidelines
- Quality of life
- Anxiety and stress
- Treatment outcomes

JMSCR Vol||13||Issue||01||Page 72-76||January

Introduction

Breast cancer is among the leading causes of cancer-related deaths in women globally.. Early detection through mammography screening has been shown to improve survival rates. However, the balance of benefits and risks of mammography screening can differ based on age, with particular debate surrounding its use in women aged 40 to 49 years. This paper examines the scientific evidence regarding the efficacy and safety of mammography screening in this age group.

Benefits of Mammography Screening Early Detection and Mortality Reduction

Mammography can detect tumors at an early stage, which is crucial for improving treatment outcomes. Studies have demonstrated a reduction in breast cancer mortality with regular mammography screening in women aged 40 to 49 years.

Table 1: Mortality Reduction from Mammography Screening in Women Aged 40-49 Years

Study	Sample Size	Follow-up Period	Mortality Reduction(%)	
		· · ·		

Study A	10,000	10 years	15
Study B	8,000	8 years	18
Study C	15,000	12 years	12

Improved Treatment Options

Early detection often results in less aggressive treatments and better cosmetic outcomes. This can significantly improve the quality of life for women diagnosed with breast cancer.

Quantitative Data on Treatment Outcomes

Studies indicate that early detection through mammography screening leads to a higher likelihood of breast-conserving surgery and less extensive lymph node removal.

Table 2: Treatment Outcomes for Early Detected Breast Cancer

Study	Breast-Conserving Surgery Rate (%) Less Extensive Lymph Node Rem		
	-		
Study G	60	70	
Study H	55	68	
Study I	58	72	

Risks of Mammography Screening False Positives and Anxiety

False positives are common in mammography screening, leading to unnecessary biopsies and anxiety.

Table 3: Rates of False Positives in Mammography Screening in Women Aged 40-49 Years				
Study	Sample Size False Positive Rate (%) Biopsies Resulting from False Positives (%			g from False Positives (%)
Study D	12,000	10	3	
Study E	9,000	12	4	
Study F	11,500	9	2.5	

2025

Overdiagnosis

Overdiagnosis involves detecting cancers that would not have caused symptoms or harm during a woman's lifetime, potentially leading to overtreatment and unnecessary side effects.

Table 4: Estimates of Overdiagnosis in Mammography Screening

Study	Sample Siz	Sample Size Overdiagnosis Rate (%)		
Study J	20,000	5		
Study K	15,000	7		
Study L	25,000	6		

Psychological Impact of False Positives

The psychological impact of false positives includes increased anxiety, stress, and potential impacts on mental health.

Table 5: Psychological Impact of False Positives

Study	Sample Size In	Sample Size Increased Anxiety Rate (%) Long-term Stress Rate (%)		
Study M	5,000	20	10	
Study N	4,000	25	12	
Study O	6,000	22	11	

Radiation Exposure

Repeated exposure to radiation from mammograms, albeit low, can slightly increase the risk of developing cancer over a woman's lifetime.

Table 6: Estimated Radiation Exposure from Mammography Screening

Number of Mammograms | Estimated Radiation Dose (mSv) | Estimated Increased Risk of Cancer (%)

0.001	0.5	5
0.002	1.0	10
0.003	1.5	15

Comparison with Natural Background Radiation

The radiation dose from mammography is compared with natural background radiation to provide context.

Table 7: Comparison of Mammography Radiation with Natural Background Radiation

Source of Radiation	Radiation Dose (mSv)
Annual natural backgroun	id 3
Single mammogram	0.1
10 mammograms over 10	years 1.0

Discussion

The benefits of mammography screening in women aged 40 to 49 years include early detection and reduced mortality, while the risks involve false positives, overdiagnosis, and radiation exposure. The decision to start regular mammography screening in this age group should be individualized, taking into consideration each woman's risk factors and personal preferences.

Individualized Risk Assessment

Factors such as family history, genetic predisposition (e.g., BRCA mutations), and breast density should be considered in personalized screening recommendations.

Comparative Effectiveness Research

Future studies should focus on comparative effectiveness to refine screening strategies and optimize benefits while minimizing risks.

Conclusion

Mammography screening in women aged 40 to 49 years presents both significant benefits and notable risks. It is imperative that healthcare providers discuss these factors with patients to make informed decisions about screening practices. Further research is needed to refine screening guidelines and reduce associated risks.

Recommendations for Healthcare Providers

- Engage in shared decision-making with patients.
- Provide comprehensive information about benefits and risks
- Consider individual risk factors in screening recommendations.

References

 Mammen D, Daniel M, Sane RT: Seasonal and Geographical Variations In Chemical Constituents of Leptadenia reticulate, International Journal of Pharmaceutical Sciences Review and Research, 2010 Volume 4, Issue 2

- 2. Anonymous: Soils, Plant Growth and Crop production- Medicinal and Aromatic Plants 2010, Volume II (Encyclopedia of Life Support Systems)
- Shah Biren, Seth, A.K.: Drug Containing Alkaloids, Textbook of Pharmacognosy and Phytochemistry 2010, First edition, Elsevier Publication
- 4. Ali, M.: Alkaloids, Textbook of Pharmacognosy, 2007, CBS Publishers & Distributors
- Kirtikar JD, Basu BD. Indian medicinal plants. Allahabad: Lalit Mohan Basu; 1994. pp. 1229–1231.
- 6. Research J. Pharmacognosy and Phytochemistry 2013; 5(3): 143-148 O. M. Singh, et al.
- Abdollahi M, Karimpour H and Monsef Esfehani H P, Antinociceptive effects of Teucrium polium L, total extract and essential oil in mouse writhing test, Pharmacology Research.48; 2003: 31-35
- Das S, Kumar P, Basu SP. Review article on phytoconstituents and therapeutic potentials of Daturastramonium linn. J Drug Del Therap. 2012;2(3):4–7.
- 9. Pretorius E, Marx J. Datura stramonium in asthma treatment and possible effects on prenatal development. Environ Toxicol Pharm. 2006;21(3):331–337
- Taha SA, Mahdi AW. Datura intoxication in Riyadh. Trans R Soc Trop Med Hgy. 1984;78:134–135.
- Takhi D, Ouinten M. Study of antimicrobial activity of secondary metabolites extracted from spontaneous plants from the area of Laghouat, Algeria. Adv EnvironmBiol. 2011;5(2):469–476.
- 12. Balachandran P, Rajgopal G. Cancer—an ayurve dicperspective. Pharm Res. 2005;51(1):19–30.
- 13. American Cancer Society. Breast Cancer Early Detection and Diagnosis. Updated

JMSCR Vol||13||Issue||01||Page 72-76||January

2025

2023. Available at: https://www.cancer.org.

- Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–1786. doi:10.1016/S0140-6736(12)61611-0
- 15. Nelson HD, Pappas M, Cantor A, et al. of breast cancer screening: Harms systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016:164(4):256-267. doi:10.7326/M15-0970
- Miller AB, Wall C, Baines CJ, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. doi:10.1136/bmj.g366
- USPSTF. Screening for Breast Cancer: Recommendations and Rationale. U.S. Preventive Services Task Force. 2016. https://www.uspreventiveservicestaskforce .org.
- Siu AL, U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(4):279–296. doi:10.7326/M15-2886
- Tabár L, Vitak B, Chen HH, et al. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001;91(9):1724–1731. doi:10.1002/1097-0142(20010501)91:9<1724::aidcncr1195>3.0.co;2-w
- 20. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;2013(6):CD001877. doi:10.1002/14651858.CD001877.pub5

- Coldman A, Phillips N, Wilson C, et al. Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer. J Natl Cancer Inst. 2014;106(11):dju261. doi:10.1093/jnci/dju261
- 22. Smith RA, Andrews K, Brooks D, et al. Cancer Screening in the United States, 2022: A Review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening. CA Cancer J Clin. 2022;72(3):363–385. doi:10.3322/caac.21700
- Nyström L, Andersson I, Bjurstam N, et al. 23. Long-term effects of mammography screening: overview of updated the Swedish randomised trials. Lancet. 2002;359(9310):909-919. doi:10.1016/s0140-6736(02)07940-7
- 24. Brodersen J, Siersma VD. Long-term psychosocial consequences of falsepositive screening mammography. Ann Fam Med. 2013;11(2):106–115. doi:10.1370/afm.1466
- 25. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening viewpoint of the IARC Working Group. N Engl J Med. 2015;372(24):2353–2358. doi:10.1056/NEJMsr1504363.